Brief: Edgewise Therapeutics Announces Sale Of Sevasemten For Up To $2.65 Billion, Strengthening Balance Sheet And Centering Company Focus On Cardiovascular Pipeline
01/06/2026 13:34
BRIEF-Edgewise Therapeutics Announces Sale Of Sevasemten For Up To $2.65 Billion, Strengthening Balance Sheet And Centering Company Focus On Cardiovascular Pipeline June 1 (Reuters) - Edgewise Therapeutics Inc EWTX.O:
EDGEWISE THERAPEUTICS ANNOUNCES SALE OF SEVASEMTEN FOR UP TO $2.65 BILLION, STRENGTHENING BALANCE SHEET AND CENTERING COMPANY FOCUS ON CARDIOVASCULAR PIPELINE
EDGEWISE THERAPEUTICS - TO RECEIVE $1.55 BILLION UPFRONT AND UP TO $1.1 BILLION IN MILESTONES
EDGEWISE THERAPEUTICS - PROCEEDS EXPECTED TO FULLY FUND EDG-7500 DEVELOPMENT THROUGH POTENTIAL APPROVAL
EDGEWISE THERAPEUTICS - ON TRACK TO REPORT 12-WEEK CIRRUS-HCM PART D DATA IN Q2 2026
EDGEWISE THERAPEUTICS - EMPLOYEES SUPPORTING MUSCULAR DYSTROPHY BUSINESS TO RECEIVE OFFERS FROM SERVIER
Source text: ID:nPn39BCVxa
Further company coverage: EWTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Edgewise Therapeutics
See all newsBrief: Edgewise Therapeutics Doses First Patient In Phase 2 Equinox-Hfpef Trial Of Edg-15400
Edgewise Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Edgewise Therapeutics Q2 net loss widens on higher expenses
Brief: Edgewise Therapeutics Q2 Operating Income USD -61.943 Million
U.S. STOCKS ON THE MOVE-RBB Bancorp, Roblox, Open Lending